{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T09:00:35Z","timestamp":1773910835483,"version":"3.50.1"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2016,3,14]],"date-time":"2016-03-14T00:00:00Z","timestamp":1457913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We report a case of a 31-year-old man with metastatic fibrolamellar hepatocellular carcinoma (FLHCC) treated with gemcitabine and oxaliplatin complicated by hyperammonemic encephalopathy biochemically consistent with acquired ornithine transcarbamylase deficiency. Awareness of FLHCC-associated hyperammonemic encephalopathy and a pathophysiology-based management approach can optimize patient outcome and prevent serious complications. A discussion of the management, literature review, and proposed treatment algorithm of this rare metabolic complication are presented.<\/jats:p>","DOI":"10.1634\/theoncologist.2015-0267","type":"journal-article","created":{"date-parts":[[2016,3,15]],"date-time":"2016-03-15T02:23:20Z","timestamp":1458008600000},"page":"514-520","source":"Crossref","is-referenced-by-count":29,"title":["Hyperammonemic Encephalopathy Associated With Fibrolamellar Hepatocellular Carcinoma: Case Report, Literature Review, and Proposed Treatment Algorithm"],"prefix":"10.1093","volume":"21","author":[{"given":"Claudia I.","family":"Chapuy","sequence":"first","affiliation":[{"name":"a Dana-Farber Cancer Institute at St. Elizabeth\u2019s Medical Center, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inderneel","family":"Sahai","sequence":"additional","affiliation":[{"name":"b Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit","family":"Sharma","sequence":"additional","affiliation":[{"name":"b Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew X.","family":"Zhu","sequence":"additional","affiliation":[{"name":"b Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga N.","family":"Kozyreva","sequence":"additional","affiliation":[{"name":"a Dana-Farber Cancer Institute at St. Elizabeth\u2019s Medical Center, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,3,14]]},"reference":[{"key":"2021122309524335200_B1","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/2050640613501507","article-title":"Fibrolamellar hepatocellular carcinoma in the USA, 2000-2010: A detailed report on frequency, treatment and outcome based on the Surveillance, Epidemiology, and End Results database","volume":"1","author":"Eggert","year":"2013","journal-title":"United European Gastroenterol J"},{"key":"2021122309524335200_B2","first-page":"743790","article-title":"Fibrolamellar carcinoma: 2012 update","volume":"2012","author":"Torbenson","year":"2012","journal-title":"Scientifica (Cairo)"},{"key":"2021122309524335200_B3","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/hep.20096","article-title":"Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study","volume":"39","author":"El-Serag","year":"2004","journal-title":"Hepatology"},{"key":"2021122309524335200_B4","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/1471-2407-5-142","article-title":"Clinical and pathologic factors associated with survival in young adult patients with fibrolamellar hepatocarcinoma","volume":"5","author":"Moreno-Luna","year":"2005","journal-title":"BMC Cancer"},{"key":"2021122309524335200_B5","first-page":"3","article-title":"Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: Data from the fibrolamellar carcinoma consortium","volume":"6","author":"Ang","year":"2013","journal-title":"Gastrointest Cancer Res"},{"key":"2021122309524335200_B6","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000354698","article-title":"Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma","volume":"85","author":"Kaseb","year":"2013","journal-title":"Oncology"},{"key":"2021122309524335200_B7","first-page":"49","article-title":"Prognosis of patients with fibrolamellar hepatocellular carcinoma versus conventional hepatocellular carcinoma: A systematic review and meta-analysis","volume":"7","author":"Njei","year":"2014","journal-title":"Gastrointest Cancer Res"},{"key":"2021122309524335200_B8","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1200\/JCO.2003.10.103","article-title":"Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma","volume":"21","author":"Patt","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122309524335200_B9","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1136\/pmj.77.913.717","article-title":"Non-hepatic hyperammonaemia: an important, potentially reversible cause of encephalopathy","volume":"77","author":"Hawkes","year":"2001","journal-title":"Postgrad Med J"},{"key":"2021122309524335200_B10","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1055\/s-0034-1370132","article-title":"[Hyperammonemic encephalopathy in multiple myeloma]","volume":"139","author":"Oestmann","year":"2014","journal-title":"Dtsch Med Wochenschr"},{"key":"2021122309524335200_B11","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/MAJ.0b013e3181bccfb4","article-title":"Hyperammonemic encephalopathy: A rare presentation of fibrolamellar hepatocellular carcinoma","volume":"338","author":"Sethi","year":"2009","journal-title":"Am J Med Sci"},{"key":"2021122309524335200_B12","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s12032-008-9121-8","article-title":"Hyperammonemic encephalopathy in a patient with primary hepatic neuroendocrine carcinoma","volume":"26","author":"Turken","year":"2009","journal-title":"Med Oncol"},{"key":"2021122309524335200_B13","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.biocel.2006.10.007","article-title":"Ornithine transcarbamylase and arginase I deficiency are responsible for diminished urea cycle function in the human hepatoblastoma cell line HepG2","volume":"39","author":"Mavri-Damelin","year":"2007","journal-title":"Int J Biochem Cell Biol"},{"key":"2021122309524335200_B14","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.jpainsymman.2014.01.002","article-title":"Acute hyperammonemic encephalopathy in a non-cirrhotic patient with hepatocellular carcinoma reversed by arginine therapy","volume":"47","author":"Shinde","year":"2014","journal-title":"J Pain Symptom Manage"},{"key":"2021122309524335200_B15","first-page":"1119","article-title":"Idiopathic hyperammonemia: A frequently lethal complication of bone marrow transplantation","volume":"17","author":"Davies","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"2021122309524335200_B16","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00001813-199306000-00003","article-title":"Transient hyperammonemia related to chemotherapy with continuous infusion of high-dose 5-fluorouracil","volume":"4","author":"Liaw","year":"1993","journal-title":"Anticancer Drugs"},{"key":"2021122309524335200_B17","first-page":"839","article-title":"[Two cases of hyperammonemic patients treated by chemotherapy for colorectal cancer]","volume":"39","author":"Aihara","year":"2012","journal-title":"Gan To Kagaku Ryoho"},{"key":"2021122309524335200_B18","first-page":"867","article-title":"[A case of hyperammonemic encephalopathy in a patient with recurrent colon cancer treated with modified FOLFOX6]","volume":"36","author":"Teraishi","year":"2009","journal-title":"Gan To Kagaku Ryoho"},{"key":"2021122309524335200_B19","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1345\/aph.1Q038","article-title":"Sunitinib-induced hyperammonemic encephalopathy in gastrointestinal stromal tumors","volume":"45","author":"Lee","year":"2011","journal-title":"Ann Pharmacother"},{"key":"2021122309524335200_B20","first-page":"453752","article-title":"Severe hyperammoniamia in late-onset ornithine transcarbamylase deficiency triggered by steroid administration","volume":"2015","author":"Gascon-Bayarri","year":"2015","journal-title":"Case Rep Neurol Med"},{"key":"2021122309524335200_B21","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/archneur.57.7.1085","article-title":"Hyperammonia possibly due to corticosteroids","volume":"57","author":"Berry","year":"2000","journal-title":"Arch Neurol"},{"key":"2021122309524335200_B22","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/archneur.57.7.1085","article-title":"Hyperammonia possibly due to corticosteroids","volume":"57","author":"Hawley","year":"2000","journal-title":"Arch Neurol"},{"key":"2021122309524335200_B23","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/jcpt.12160","article-title":"Regorafenib-induced hyperammonemic encephalopathy","volume":"39","author":"Kuo","year":"2014","journal-title":"J Clin Pharm Ther"},{"key":"2021122309524335200_B24","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1345\/aph.1M457","article-title":"Sorafenib-induced hepatic encephalopathy","volume":"43","author":"Marks","year":"2009","journal-title":"Ann Pharmacother"},{"key":"2021122309524335200_B25","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/8904_2014_318","article-title":"Fibrolamellar hepatocellular carcinoma mimicking ornithine transcarbamylase deficiency","volume":"16","author":"Sulaiman","year":"2014","journal-title":"JIMD Rep"},{"issue":"1157","key":"2021122309524335200_B26","first-page":"1401","article-title":"An 18-year-old woman with a 15-cm liver mass and an ammonia level of 342","volume":"143","author":"Hashash","year":"2012","journal-title":"Gastroenterology"},{"key":"2021122309524335200_B27","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/SMJ.0b013e31816bf5cc","article-title":"Postchemotherapy hyperammonemic encephalopathy emulating ornithine transcarbamoylase (OTC) deficiency","volume":"101","author":"Chan","year":"2008","journal-title":"South Med J"},{"key":"2021122309524335200_B28","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/j.jpainsymman.2015.03.007","article-title":"Treatment of paraneoplastic hyperammonemia in fibrolamellar hepatocellular carcinoma with oral sodium phenylbutyrate","volume":"49","author":"Bender","year":"2015","journal-title":"J Pain Symptom Manage"},{"key":"2021122309524335200_B29","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1002\/hep.27018","article-title":"Transcriptional profiling of pure fibrolamellar hepatocellular carcinoma reveals an endocrine signature","volume":"59","author":"Malouf","year":"2014","journal-title":"Hepatology"},{"key":"2021122309524335200_B30","volume-title":"Rare Diseases Clinical Research Network. 2015","author":"Urea Cycle Disorders Consortium"},{"key":"2021122309524335200_B31","first-page":"69","article-title":"Sodium benzoate and arginine: alternative pathway therapy in inborn errors of urea synthesis","volume":"127","author":"Batshaw","year":"1983","journal-title":"Prog Clin Biol Res"},{"key":"2021122309524335200_B32","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1056\/NEJM198206103062303","article-title":"Treatment of inborn errors of urea synthesis: Activation of alternative pathways of waste nitrogen synthesis and excretion","volume":"306","author":"Batshaw","year":"1982","journal-title":"N Engl J Med"},{"issue":"(2)","key":"2021122309524335200_B33","first-page":"CD003044","article-title":"Nonabsorbable disaccharides for hepatic encephalopathy","author":"Als-Nielsen","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"2021122309524335200_B34","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","article-title":"Rifaximin treatment in hepatic encephalopathy","volume":"362","author":"Bass","year":"2010","journal-title":"N Engl J Med"},{"issue":"suppl","key":"2021122309524335200_B35","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.ccc.2005.08.003","article-title":"Nutritional management of urea cycle disorders","volume":"21","author":"Singh","year":"2005","journal-title":"Crit Care Clin"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2015-0267","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2015-0267","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/21\/4\/514\/41874839\/oncolo_21_4_514.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/21\/4\/514\/41874839\/oncolo_21_4_514.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T04:15:31Z","timestamp":1640319331000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/21\/4\/514\/6401332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,14]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,3,14]]},"published-print":{"date-parts":[[2016,4,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2015-0267","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,4,1]]},"published":{"date-parts":[[2016,3,14]]}}}